We are pleased to announce that our recent literature review on emerging molecular testing in lung cancer, authored by Prof. Frédérique Penault-Llorca and Prof. Mark Socinski, has been published by The Oncologist.
The paper is titled:
Emerging molecular testing paradigms in NSCLC management - current perspectives and recommendations
For an overview of the publication, see the slides in the Downloadable Resources section.
The full publication can be accessed at: Emerging molecular testing paradigms in non-small cell lung cancer management—current perspectives and recommendations | The Oncologist | Oxford Academic
Clinical takeaways
- Precision medicine in patient care requires specialised knowledge that is best delivered via a well-coordinated and well-educated MDT, up to date with the latest developments in lung biomarker research and testing technology
- Molecular testing should be performed in clinical situations where there is evidence that targeting particular molecular alterations makes a clinical difference
- Specimen acquisition and processing of tissue should follow well-established standard procedures and protocols. Genomic testing with NGS using multigene panels is highly recommended
- Besides methodological aspects, effective collaboration and communication within the MDT are paramount
- Patients should be evaluated by MDTs implementing rapid on-site evaluation (ROSE) and reflex testing to improve testing efficiency and reduce the time to treatment initiation
Download slides - PDF 
Duration
Language(s)
Downloadable 
8 MIN
Apr 2025 
